|
|
Vaccine Detail
|
Melanoma Theraccine |
| Vaccine Information |
- Vaccine Name: Melanoma Theraccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007523
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- IFNL3
gene engineering:
- Description: A synthetic allogeneic cancer vaccine. Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with an adjuvant (such as DETOX or RIBI). This agent may be combined with immunomodulatory cytokines such as interferon alpha. Melanoma theraccine may induce a rise in the level of cytotoxic T-lymphocyte precursors. (NCIT_C1830).
|
| Host Response |
|
|
| References |
Mitchell et al., 1994: Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994; 12(2); 402-411. [PubMed: 8113848].
NCIT_C1830: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1830]
|
|
